[a. Forest plot. Effect of antiresorptive medications preventing secondary vertebral fracture. 3](#_Toc501984025)

[b. Forest plot. GI complaints of bisphosphonates. 4](#_Toc501984026)

[c. Forest plot. Discontinuation due to AEs – Zoledronate 5](#_Toc501984027)

[d. Forest plot. Preventing non-vertebral fracture – Zoledronate 5](#_Toc501984028)

[e. Forest plot. GI complaints - Alendronate 5](#_Toc501984029)

[f. Forest plot. Discontinuation due to AEs – Alendronate 5](#_Toc501984030)

[g. Forest plot. Non-vertebral fracture – Alendronate 6](#_Toc501984031)

[h. Forest plot. GI complaints – Risedronate 7](#_Toc501984032)

[i. Forest plot. Discontinuation due to AEs - Risedronate 7](#_Toc501984033)

[j. Forest plot. Non-vertebral fracture – Risedronate 7](#_Toc501984034)

[k. Forest plot. Sensitivity test. Excluding a study with a small sample size and big variance with other studies. 8](#_Toc501984035)

[l. Forest plot. GI complaints – Etidronate 8](#_Toc501984036)

[m. Forest plot. Discontinuation – Etidronate 8](#_Toc501984037)

[n. Forest plot. Non-vertebral fracture – Etidronate 9](#_Toc501984038)

[o. Forest plot. Discontinuation due to AEs – Ibandronate (sufficient dose) 9](#_Toc501984039)

[p. Forest plot. Discontinuation due to AEs – Ibandronate (insufficient dose) 9](#_Toc501984040)

[q. Forest plot. Non-vertebral fracture – Ibandronate (sufficient dose) 9](#_Toc501984041)

[r. Forest plot. Non-vertebral fracture – Ibandronate (insufficient dose) 10](#_Toc501984042)

[s. Forest plot. Non-vertebral fracture – Minodronate 10](#_Toc501984043)

[t. Forest plot. Non-vertebral fracture – Pamidronate 10](#_Toc501984044)

[u. Forest plot. Non-vertebral fracture – HRT 10](#_Toc501984045)

[v. Forest plot. Discontinuation due to AEs – HRT 11](#_Toc501984046)

[w. Forest plot. Discontinuation due to AEs – PTH 11](#_Toc501984047)

[x. Forest plot. Non-vertebral fracture – PTH 12](#_Toc501984048)

[y. Forest plot. Discontinuation due to AEs – Denosumab 12](#_Toc501984049)

[z. Forest plot. Non-vertebral fracture – Denosumab 12](#_Toc501984050)


[aa. Forest plot. Discontinuation – Risedronate vs. PTH 13](#_Toc501984051)

[bb. Forest plot. Non-vertebral fracture – Teriparatide vs. Risedronate 13](#_Toc501984052)


[cc. Forest plot. Non-vertebral fracture – Alendronate vs. Denosumab 13](#_Toc501984053)

[cc. Forest plot. Non-vertebral fracture – Romosozumab vs. Alendronate 13](#_Toc501984054)


# a. Forest plot. Effect of antiresorptive medications preventing secondary vertebral fracture.




# b. Forest plot. GI complaints of bisphosphonates.




# c. Forest plot. Discontinuation due to AEs – Zoledronate




# d. Forest plot. Preventing non-vertebral fracture – Zoledronate




# e. Forest plot. GI complaints - Alendronate




# f. Forest plot. Discontinuation due to AEs – Alendronate




# g. Forest plot. Non-vertebral fracture – Alendronate




# h. Forest plot. GI complaints – Risedronate




# i. Forest plot. Discontinuation due to AEs - Risedronate




# j. Forest plot. Non-vertebral fracture – Risedronate




# k. Forest plot. Sensitivity test. Excluding a study with a small sample size and big variance with other studies.




# l. Forest plot. GI complaints – Etidronate




# m. Forest plot. Discontinuation – Etidronate




# n. Forest plot. Non-vertebral fracture – Etidronate




# o. Forest plot. Discontinuation due to AEs – Ibandronate (sufficient dose)




# p. Forest plot. Discontinuation due to AEs – Ibandronate (insufficient dose)




# q. Forest plot. Non-vertebral fracture – Ibandronate (sufficient dose)




# r. Forest plot. Non-vertebral fracture – Ibandronate (insufficient dose)




# s. Forest plot. Non-vertebral fracture – Minodronate




# t. Forest plot. Non-vertebral fracture – Pamidronate




# u. Forest plot. Non-vertebral fracture – HRT




# v. Forest plot. Discontinuation due to AEs – HRT




# w. Forest plot. Discontinuation due to AEs – PTH




# x. Forest plot. Non-vertebral fracture – PTH




# y. Forest plot. Discontinuation due to AEs – Denosumab




# z. Forest plot. Non-vertebral fracture – Denosumab




# aa. Forest plot. Non-vertebral fracture – Ibandronate vs. Risedronate



# bb. Forest plot. Discontinuation – Risedronate vs. PTH



# cc. Forest plot. Non-vertebral fracture – Teriparatide vs. Risedronate



# dd. Forest plot. Non-vertebral fracture – Alendronate vs. Denosumab



# ee. Forest plot. Non-vertebral fracture – Romosozumab vs. Alendronate

